Biosimilars Guidances To Focus On Naming, Tracking, Defining “Protein”
This article was originally published in The Pink Sheet Daily
Executive Summary
Without offering a timeline for release, CDER’s Rachel Sherman says the documents will also address exclusivity issues, as well as specifying what constitutes “publicly available” information regarding FDA’s previous determination of safety, purity and potency.
You may also be interested in...
Biosimilar User Fee Agreement Allows For Reliance On Foreign Clinical Data, FDAer Says
Agency interactions with sponsors under BsUFA are not dependent upon opening an IND. Sponsors may be able to demonstrate similarity to an FDA-licensed reference product by bridging to foreign clinical data, Associate Director for Biosimilars Leah Christl says.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.